Press release: Uppsala,
Dicot is developing a new potency drug with the aim to treat erectile dysfunction and premature ejaculation better than existing drugs. The company has previously announced its intention to start clinical studies with the drug candidate LIB-01 in mid-2023.
For GMP (Good Manufacturing Practice) manufacturing of study drug to be used in the phase 1 clinical trials, Dicot has contracted
"We are very happy to engage with such an experienced and highly regarded drug manufacturer as
For further information, please contact:
Tel: +46 739 80 14 08
Email: elin.trampe@dicot.se
About Dicot AB
Dicot is developing the drug candidate LIB-01, which will be a potency agent to better treat erectile dysfunction and premature ejaculation. The ambition is to create a drug with significantly longer effect and far fewer side effects, compared to current available drugs. Today, over 500 million men suffer from these sexual dysfunctions and the market is valued at
Dicot is listed on
https://news.cision.com/dicot-ab--publ-/r/dicot-has-contracted-thermo-fisher-scientific-for-manufacturing-of-lib-01,c3700067
https://mb.cision.com/Main/17172/3700067/1791303.pdf
(c) 2023 Cision. All rights reserved., source